Abstract : In this issue of Cancer Cell, Dahan and colleagues demonstrate that modified Fc regions of agonistic anti-human CD40 mAbs can drastically increase their efficiency in a mouse pre-clinical model expressing human CD40 and IgG receptors. This study also highlights the fine balance between increased treatment efficacy and secondary side effects.
https://hal-pasteur.archives-ouvertes.fr/pasteur-02578652 Contributor : Marie MartinConnect in order to contact the contributor Submitted on : Tuesday, November 3, 2020 - 1:28:10 PM Last modification on : Thursday, April 7, 2022 - 1:58:18 PM Long-term archiving on: : Thursday, February 4, 2021 - 6:32:19 PM
Pierre Bruhns, Jean-Luc Teillaud. Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy. Cancer Cell, Elsevier, 2016, 29 (6), pp.771-773. ⟨10.1016/j.ccell.2016.05.009⟩. ⟨pasteur-02578652⟩